The neuronal growth-associated protein GAP-43 is expressed during axonal outgrowth and regeneration (for review, see Benowitz and Routtenberg, 1987) . In the present study, we demonstrate that GAP-43 is constitutively expressed by NBPaldl neuroblastoma cells. The initial, most rapid outgrowth period of neuritogenesis [O-4 hr after dibutyryl adenosine 3',5'-cyclic monophosphate (dbcAMP) treatment] is accompanied by intense GAP-43 immunoreactivity along the entire length of most neurites. However, this immunoreactivity declined nearly to background levels within hours during continued neurite outgrowth and persisted only at varicosities and growth cones. GAP-43 was detectable by metabolic labeling and immunoblot analysis in undifferentiated cells, and synthetic rates and steady-state levels of GAP-43 underwent only a modest (approximately twofold) increase during dbcAMP-induced differentiation. Unlike levels observed in neurites, perikarya of undifferentiated and differentiated cells contained similar, intense levels of GAP-43 immunoreactivity.
Neurite elaboration and GAP-43 immunoreactivity were unaffected by treatment with cycloheximide, suggesting that translocation of perikaryal GAP-43 pools, rather than de nova synthesis, contributes to the transient burst of GAP-43 observed in developing neurites. Phosphatidylcholine-mediated delivery of anti-GAP-43 antibodies (aGAP) into cells immediately before dbcAMP treatment arrested neuritogenesis but did not induce the retraction of existing neurites. These results indicate that, while GAP-43 expression is insufficient to induce neuritogenesis in NBSa/dl cells, GAP-43 is nevertheless essential for the initial, dynamic phase of neurite outgrowth.
The development and restructuring of neuronal connections involve the coordinate expression of numerous cellular constituents, one of which is the membrane-associated phosphoprotein GAP-43 (also known as B50, Fl, pp46, GAP48, ~57, neuromodulin; Benowitz and Routtenberg, 1987; Skene, 1989) . Neurons express high levels of this protein during axogenesis and synaptogenesis, at which time it is abundant along the entire axonal length and in growth cones (Meiri et al., 1988; Moya et al., 1989; Dani et al., 1990; Goslin et al., 1990b) . Axonal regeneration and reactive synaptogenesis are likewise marked by a resurgence of GAP-43 expression (Benowitz and Routtenberg, 1987; Skene, 1989; Benowitz et al., 1990) . Although overall levels of this protein decline sharply in most of the brain following the establishment of mature synapses (Jacobson et al., 1986; McGuire et al., 1988 ) certain brain regions continue to have considerable levels of GAP-43 throughout life (Gispen et al., 1985; Nelson et al., 1987; Benowitz et al., 1988; Neve et al., 1988) , where its presence has been linked to signal transduction mechanisms that regulate the function and structure of presynaptic endings (Jolles et al., 1980; Lovinger et al., 1985; Alexander et al., 1987; Freeman et al., 1988; Dekker et al., 1989) .
With regard to the causal role of this protein in axonal outgrowth, transfection of the GAP-43 gene has been reported to increase the extension of filopodial processes in Cos cells (Zuber et al., 1989) and to accelerate the NGF-mediated outgrowth of neurites and increase sensitivity to NGF in PC 12 pheochromocytoma cells (Yankner et al., 1990) . However, in transformed cell lines of embryonic brain origin, though GAP-43 is constitutively expressed, neuritogenesis does not occur spontaneously and requires the addition of other agents (Megerian et al., 1989) . To investigate further the role of GAP-43 expression in neurite outgrowth, we used L-cu-lysophosphaditylcholine (LPC, Nomura et al., 1986; Shea and Beermann, 199 1) to introduce anti-GAP-43 antibodies into NB2a/dl neuroblastoma, a cell line that elaborates axonal processes following treatment with dibutyryl CAMP and other agents (Shea et al., 1985 (Shea et al., , 1988 (Shea et al., , 1991a . Our results indicate that, though GAP-43 expression by itself is not sufficient to cause NB2a/d 1 cells to extend net&es, in conjunction with other factors it is required for axonal outgrowth to occur.
Portions of this research have been presented in abstract form (Shea et al., 199 1 b) .
Materials and Methods
CeflcuZfure. NB2a/dl cells (Shea et al., 1985) were cultured and induced to extend axonal neurites by the addition of 1 mM dibutyryl adenosine 3',5'-cyclic monophosphate (dbcAMP; Sigma Chemical-Co.) or serum deprivation as described previouslv (Shea et al.. 1985 (Shea et al.. . 1988 ) 24 hr after the initial plating for O,-4, 24, or 72 hr. Cycloheximide (0.5 &ml; Sigma) was added to some cultures 90 min before dbcAMP. Quantitation of neurite outgrowth. At 4 or 24 hr after the above treatments, duplicate cultures were rinsed in Tris-buffered saline (TBS; pH, 7.4), fixed for 10 min in 4% paraformaldehyde in 0.1 M phosphate buffer (pH, 7.2) at room temperature for 15 mitt, then rinsed and stored in TBS. All experiments were carried out at least twice. In each experiment, between 100 and 200 cells in each of the fixed cultures were examined by phase-contrast microscopy. The relative extent of neurite Figure I . NB2a/dl cells extend neurites within a few hours of dbcAMP treatment, and this does not appear to require the synthesis of new proteins. Cells were treated with 1 mM dbcAMP for 0 (A), 4 (B), 24 (C), or 72 hr (0). Cycloheximide had no detectable effect on initial (4 hr) neurite outgrowth (E).
outgrowth was quantitated by comparison of neurite length with respective somal diameter (SD). Previous quantitative studies of NB2a/ dl neurite outgrowth (Shea et al., 1985 (Shea et al., , 1991b have shown that the majority of undifferentiated NB2a/dl cells possess putative neurites of < 1 SD, while the respective modal length of neurites induced by various treatments is l-2 SD at 4 hr and 2-3 SD at 24 hr. Accordingly, for analyses of neurite induction at 4 hr, the percentage of cells per culture with neurites was determined by calculating (mean number of cells with 2 I-SD net&es/mean number of total cells scored) x 100, and the percentage of cells per culture with neurites at 24 hr, by calculating (mean number of cells with 2 2-SD neurites/mean number of total cells scored) x 100 as described previously (Shea et al., 199 1 b) . Ratios of cells with or without neurites were statistically compared by Student's t test.
Immunocytochemistry. Cultures were fixed with 4% paraformaldehyde and reacted with a 1: 1000 dilution of the IgG fraction derived from a sheep polyclonal antibody directed against GAP-43 or the respective preimmune IgG fraction @GAP, Benowitz et al., 1988) followed by a 1: 1000 dilution of a biotinylated goat anti-sheep antibody (ICN Immunochemicals, Naperville, MD), then stained with the avidinbiotin complex (ABC) conjugated to horseradish peroxidase and diaminobenzidine (Sigma) as described (Shea et al., 1988) .
Gel electrophoresis and immunoblot analysis. Triton-soluble proteins from undifferentiated cultures and cultures treated with dbcAMP for 24 hr (200 118) were electrophoresed on SDS-6% polyacrylamide gels, transferred to nitrocellulose, reacted with a monospecific antibody to GAP-43 (at a 1:2000 dilution in Tris-buffered saline overnight at room temperature), and visualized as described (Shea et al., 1988) . Figure 2 . GAP-43 is expressed constitutively in NBZa/dl cells and is abundant in newly growing neurites. Cells were treated with 1 mM dbcAMP for 0 (a), 4 (b), 12 (c), 16 (d), and 24 hr (e), after which cultures were fixed and immunostained with LYGAP. Whereas the filopodia-like neurites of untreated cells are unstained (arrows, a), dbc-AMP-induced neurites show intense staining for GAP-43 along their entire length by 4 hr, after which levels remain intense only in select varicosities (arrows, c-e) or growth cones (arrowheads, c and d). Perikaryal staining, by contrast, is high even in untreated cells and does not change appreciably during differentiation (a-e).
Radiolabeling. NBZa/dl cells were radiolabeled in vivo for 4 hr with a mixture of 'YS-methionine plus cysteine (Tran@S, ICN, Irvine, CA), and the patterns of protein labeling were visualized on 2-D gel fluorograms as described (Perrone-Bizzozero et al., 1986; Shea et al., 1988) . Quantitation of radiolabel incorporated into individual proteins was carried out using the Visage-100 computer densitometry system as described (Fischer and Shea, 199 1) .
Permeabilization of ceils and intracellular delivery of antibody. Antibodies were loaded into cells by the procedure of Nomura et al. (1986) as modified by Shea and Beermann (1991) . Cells (50-75% confluent) in 35-mm2 Petri dishes were rinsed with serum-free Dulbecco's modified Eagle's medium (DMEM) and treated with 1 ml prewarmed (37°C) 1.2 M glycerol in phosphate-buffered saline (pH, 7.4). Cells were then incubated at 0°C for 10 min (by placing the culture plates directly on ice), after which L-a-lysophosphatidylcholine (LPC, Sigma Chemical Co.) was added to a final concentration of 40 rg/ml, and the incubation continued for an additional 8 min. One milliliter of prewarmed (37°C) serum-free DMEM containing no antibody or 1:20 dilutions of (UGAP, a polyclonal antibody raised in this laboratory against the high-molecular-weight neurofilament subunit ((uNF-H) or their respective preimmune sera, were then added to cultures incubating with the glycerol-LPC solution, and the cultures were immediately returned to the 37°C incubator for 10 min. Cells regained impermeability during this incubation, as ascertained by the recovery of trypan blue exclusion (Shea and Beermann, 1991) . Cultures then received an additional 1 ml of prewarmed medium containing 10% horse serum and dbcAMP and were incubated for 4 hr, after which they were fixed and examined by phase-contrast microscopy. Loaded cells were not monitored for periods t, (Y-and p-tubulins; a, actin; p and q, polypeptides previously described in cerebrocortical neuronal cultures (Perrone-Bizzozero et al., 1986). E and F, Immtmocytochemical analyses of GAP-43 distribution after 4 hr of dbcAMP treatment in the absence (E) and presence (F) ofcycloheximide. Neither neuritogenesis nor the appearance of GAP-43 immunoreactivity within neurites appears to be affected by the inhibition of protein synthesis (see also Fig. 1E ).
longer than 4 hr due to the likelihood of antibody degradation. Permeabilized cells elaborated neurites following dbcAMP treatment at a rate indistinguishable from nonpermeabilized cells. In all experiments, successful loading of antibody was confirmed by reaction of cells with goat anti-sheep IgG and visualization as described above.
Results
Expression of GAP-43 by NBta/dl cells NBZa/d 1 cells elaborate axonal neurites that are detectable within 4 hr after the addition of dbcAMP (Fig. 1 A, B) ; these neurites continue to elongate over the next 7 d, though at a slower rate (Fig. lC,D) . Inhibition of protein synthesis by cycloheximide treatment does not interfere with neuritogenesis (Fig. lE) , in agreement with previous observations (Shea et al., 1991a) .
NB2a/dl cells express moderately high levels of GAP-43 even prior to the induction of neuritogenesis (Figs. 2a, 3A) . Treatment with dbcAMP causes only a small overall increase in GAP-43 levels, as assessed by immunocytochemistry, Western blots, and protein synthesis (Figs. 2a-e 3A-D) . However, with the induction of process outgrowth, high levels of the protein became evident along the entire length of newly growing neurites (Fig. 2b) . GAP-43 levels in newly growing neurites exceed those in the filopodia-like neurites of nontreated cells (Fig. 2a,b) . Neu- Figure 4 . Antibodies to GAP-43 arrest neuritogenesis. Antibodies were loaded into NBZa/dl cells by the procedure of Nomura et al. (1986) as modified by Shea and Beermann ( 199 1) . Permeabilized cells were exposed to no antibody (A) or to 1:20 dilutions of cvGAP preimmune serum (B), (YGAP (c), CYNF-H preimmune serum (D), or CYNF-H (E), then treated with dbcAMP for 4 hr, after which they were fixed and examined by phasecontrast microscopy. Restriction of neuritogenesis and rounding of bodies were found only in cells exposed to aGAP (C). rite staining then declines over the next 20 hr of dbcAMP treatUndifferentiated NB2a/dl cells continuously extend and rement and is quite low at 7 d (Fig. 2e) . Cycloheximide treatment, tract short filopodia-like neurites (see, e.g., Fig. 2a) , and treatwhich does not interfere with neuritogenesis, does not alter the ments that induce neurite outgrowth may do so by stabilizing time course or intensity of GAP-43 immunoreactivity in neuthese filopodia and promoting their continued outgrowth (Shea rites (Fig. 3E,F) . Thus, at least a portion of the GAP-43 that is et al., 199 la). To examine whether the basal expression of GAPseen within newly elaborated neurites must be derived from the 43 by undifferentiated NB2a/dl cells was correlated with the pool that is already present within perikarya prior to differenelaboration of unstable filopodia-like neurites, cells were cultiation; however, as noted previously (Megerian et al., 1989) , tured in suspension, a condition under which filopodia-like neuthe presence of this pool is not in and ofitself enough to stimulate rites are not elaborated. However, immunoblot analysis and neurite outgrowth without the addition of other stimulatory metabolic labeling revealed that suspended and adherent cells factors.
expressed similar levels of GAP-43 (not shown). Transiently permeabilized cells were exposed to 1:20 dilutions of immune or preimmune sera in culture medium at 0 or 24 hr after the induction of axonal neuritogenesis by dhcAMP. All cultures were incubated with dhcAMP for an additional 4 in, then immediately fixed and examined by phase-contrast microscopy. Neurite outgrowth was quantitated as described in Materials and Methods. Values represent the mean k standard deviation. * Statistically different from controls @ < 0.0005).
Role of GAP-43 in axonal outgrowth
In order to examine whether GAP-43 is required for neuritogenesis to occur, antibodies to the protein were introduced into NB2a/dl neuroblastoma. The cells were transiently permeabilized in the presence or absence of anti-GAP antibodies @GAP), then treated with dbcAMP for 4 hr to induce neuritogenesis. In control cultures loaded with aGAP preimmune serum, neurite outgrowth was virtually identical to that obtained in the absence of antibody, as measured by the ratio of cells possessing neurites of 2 1 SD compared to those possessing neurites of < 1 SD (Table 1) . In contrast, loading cells with aGAP almost completely arrested neurite outgrowth, with an approximately 90% reduction in this ratio (Table 1 , Fig. 4) . Moreover, cells loaded with (uGAP actually appeared to be less differentiated than control cells loaded with preimmune or no serum, with substantially less polygonal somata and fewer filopodia (Fig. 4) . The effects of the antibody treatment were dose dependent: exposure of permeabilized cells to serial dilutions of (uGAP progressively lessened the inhibitory effect on neuritogenesis; anti-GAP-43 antibodies also inhibited outgrowth of axonal neurites in response to serum deprivation (not shown). Loading of (wGAP at Figure 5 . Cytochemical demonstration of antibody uptake. Cells were permeabilized, exposed to olGAP (A) or no antibody (B), treated with dbcAMP for 4 hr, fixed and reacted with peroxidase-conjugated goat anti-sheep IgG, and visualized as described in Materials and Methods. Cells exposed to (uGAP during permeabilization showed cytoplasmic staining (A) and little neurite outgrowth, whereas cells not exposed to the primary antibody showed little staining and elaborated neurites (arrows, B). Note that, in cuGAP-treated cultures, individual cells that had internalized relatively little (YGAP (as evidenced by low staining levels) did show neurite outgrowth (arrow, A).
24 hr, a time at which GAP-43 levels normally decline and neurite outgrowth slows down, did not cause existing neurites to retract (Table 1 ). This demonstrates that the antibody does not have general cytotoxic effects on these cells. As an additional control, we used an antibody directed against an extensively phosphorylated form of (YNF-H, a cytoskeletal component that is present in a soluble form in undifferentiated NB2a/dl cells but not incorporated into the axonal cytoskeleton until 3 d after the addition of the dbcAMP (Shea et al., 1988) . As shown in Figure 4 and in Table 1 , olNF-H, unlike aGAP, did not affect neuritogenesis.
To confirm that permeabilized cells had successfully taken up antibodies, cultures that had been treated with (uGAP after LPC were reacted with a biotinylated goat anti-sheep antibody, then stained with ABC conjugated to HRP and diaminobenzidine. This procedure also afforded the opportunity to examine whether the internalization of (YGAP correlated with the arrest of neurite outgrowth in individual cells. As shown in Figure 5 , NB2a/d 1 cells that internalized significant levels of aGAP showed little differentiation, whereas cells with relatively little primary antibody did elaborate neurites (Fig. 5) . Exposure of cells to olGAP without permeabilization did not affect neuritogenesis, nor did it result in specific cytochemical staining (not shown).
Discussion
It has been proposed that GAP-43 participates in neuritogenesis by altering the rate at which new membrane is added to growth cones (Meiri et al., 1988; Gordon-Weeks, 1989) . The observation that GAP-43 levels in neurites are maximal at the time at which outgrowth is occurring, that is, within the first few hours of dbcAMP treatment (Shea et al., 1985) , is consistent with this hypothesis. Moreover, the observations that neurites at later time points have much lower levels of GAP-43 and that the introduction of (uGAP does not cause existing neurites to retract suggest that GAP-43 is particularly involved in the initial, active phase of neurite outgrowth. Because continued neurite elongation has slowed dramatically by 24 hr of dbcAMP treatment, it is difficult to determine whether or not arGAP slows down later stages of axonal elongation.
The localization of GAP-43 in the neurites of cultured cells during the most active phase of outgrowth corresponds to the situation observed in vivo, where the protein is densely concentrated along elongating axons (McGuire et al., 1988; Meiri et al., 1988; Moya et al., 1989; Dani et al., 1990; Goslin et al., 1990b) . As neural development proceeds, the protein becomes less concentrated in the proximal portions of the axon and appears only in more distal segments, that is the growth cone and developing synapses (McGuire et al., 1988; Meiri et al., 1988; Moya et al., 1989; Dani et al., 1990) . In much of the brain, this stage also lasts only briefly before levels of the protein in the neuropil begin to decline (Jacobson et al., 1986; McGuire et al., 1988; Dani et al., 1990) . However, unlike neurons growing in vivo, levels of GAP-43 are high in the perikarya of NBZa/dl and other neuroblastoma cell lines (Megerian et al., 1989 ) even prior to axonal neuritogenesis. Because cycloheximide fails to disrupt the outgrowth and appearance of GAP-43 in neurites, it would seem that these events involve translocation of proteins from the preexisting perikaryal pools and do not require novel protein synthesis (Goslin et al., 199Oa) .
Axogenesis is unquestionably a very complex phenomenon, involving the coordinate action of multiple factors acting on the expression and modification of numerous cellular constituents. Our results indicate that at least one of these constituents, the growth-associated phosphoprotein GAP-43, is essential for axonal elongation to occur. However, it is also clear that the expression of this protein in NB2a/dl is not sufficient to induce neurite outgrowth, and that other cellular changes are required for this process. For example, disruption of the submembrane actin network or altering membrane adhesiveness and the availability of cytoskeletal precursors induces rapid neurite outgrowth in NB2a/dl cells (Shea, 1990) , whereas inhibiting microtubule polymerization prevents these changes from occurring (Shea, 1990; Shea et al., 199 lb) . The identification of GAP-43 as one of the critical constituents in axogenesis is one step in understanding the complex orchestration of molecular events that underlie the development of neuronal circuitry.
